Chemotherapy of Fungal Diseases

1. Front Matter

   Pages I-XXV

   PDF

2. Drug Discovery

   1. Introduction

      • John F. Ryley

      Pages 1-2

   2. Drug Discovery: A Chemist’s Approach

      • F. Thomas Boyle

      Pages 3-30

   3. Drug Discovery: A Biochemist’s Approach

      • David Kerridge, Hugo Vanden Bossche

      Pages 31-76

   4. Drug Discovery: Nature’s Approach

      • Manuel Debono, Robert S. Gordee

      Pages 77-109

   5. Screening and Evaluation In Vitro

      • Robert F. Wilson, John F. Ryley

      Pages 111-128

   6. Screening and Evaluation In Vivo

      • John F. Ryley

      Pages 129-147

3. Drug Development

   1. Introduction

      • John F. Ryley

      Pages 149-151

   2. Mode of Action Studies

      • Annemarie Polak

      Pages 153-182

   3. Pharmacokinetic Aspects of Antifungal Therapy

      • Michael H. Tarbit

      Pages 183-204

   4. Hepatic and Endocrine Effects of Azole Antifungal Agents

      • Michael H. Tarbit, William R. Robertson, Ann Lambert

      Pages 205-229

   5. Structure-Teratogenicity Relationships Among Antifungal Triazoles

      • Oliver P. Flint, F. Thomas Boyle

      Pages 231-249

   6. Formulation

      • Heinz Hänel, Wolfgang Ritter

      Pages 251-278

   7. Regulatory Procedures

      • Sarah C. Eardley

      Pages 279-311

   8. Clinical Trials

      • Thomas C. Jones, John J. Stern

      Pages 313-331

4. Clinical Usage

   1. Introduction

      • John F. Ryley

      Pages 333-334

   2. Clinical Usage — A Dermatologist’s Viewpoint

      • Marguerite M. Roberts

      Pages 335-363

   3. Therapeutic Considerations in Fungal Vaginitis

      • Jack D. Sobel

      Pages 365-383

   4. An Infectious Disease Specialist’s Viewpoint

      • Alan M. Sugar

      Pages 385-397

   5. Management of Fungal Infections in Patients with Neoplastic Diseases

      • Thomas J. Walsh, Philip A. Pizzo

      Pages 399-419

Fungal diseases have been with us from antiquity; interest in the chemo­ therapy of fungal disease has exploded in the past decade. To plan and pro­ duce a book on the topic of antifungal chemotherapy has come as a personal challenge - and something of an eye-opener - towards the end of my re­ search career. A landmark publication which still merits reading is Antifungal Chemotherapy (John Wiley & Sons, Chichester, UK), edited by David Speller, which appeared in 1980. However, the fact that ketoconazole, the first of the modern, orally active, wide-spectrum antifungals, attracted no more than two sentences in it indicates just how far we have come in the 1980s. A steady stream of original papers and a number of conference proceedings have chronicled this progress in drug research; outstanding among the latter are the proceedings of an international telesymposium, entitled Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, edited by Robert Fromtling (J.R. Prous, Barcelona, 1987) and volume 544 of the Annals of the New York Academy of Sciences, entitled Antifungal Drugs, edited by Vassil St. Georgiev, and containing papers and posters presented at a most enjoyable 3-day conference held at Garden City, New York, in the autumn of 1987.

• Chemotherapeutikum
• Mykose
• Pilzkrankheit
• chemotherapy
• drug
• drug discovery
• screening

• ICI Pharmaceuticals, Macclesfield, Cheshire, England

  John F. Ryley

Policies and ethics